MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/crocol/otag092

Медицинская библиотека · Crohn's & colitis 360 · 2026

Most of moderate to severe ulcerative colitis patients in academic clinical practice still do not qualify for randomized controlled trials.

Elmasry Sandra, Pasha Shabana, Kaur Manreet, Leighton Jonathan A, Gurudu Suryakanth R, Ha Christina

СтатьяПеревод в очереди

Аннотация

BACKGROUND

While biologic and small molecule therapies have expanded treatment options for moderate to severe ulcerative colitis (UC), prior research revealed that only 26% of patients in routine practice would have qualified for pivotal randomized controlled trials (RCTs) due to stringent eligibility criteria. This study aimed to evaluate contemporary clinical trial eligibility for UC patients in a tertiary care setting based on more recently approved therapies.

METHODS

We performed a retrospective cohort study of adult patients with moderate to severe UC (total Mayo score ≥6) seen between January 2022 and February 2023. Inclusion and exclusion criteria from seven phase III RCTs conducted between 2012 and 2022 (eg, VARSITY, UNIFI, OCTAVE, LUCENT) were applied to determine patient eligibility and identify reasons for ineligibility.

RESULTS

Of 150 patients (mean age 44.9 years; 55.7% male), only 42.7% were eligible for at least one RCT. The most common exclusion factor was current or prior medication use, followed by anemia, dysplasia, and disease extent. Trial eligibility did not significantly differ by age, gender, or disease duration.

CONCLUSIONS

Despite modest improvements since 2012, over half of real-world UC patients remain ineligible for current RCTs. Expanding inclusion criteria, especially regarding prior medication exposure, and adopting more inclusive trial designs may enhance external validity. Addressing disparities in trial access and participation remains essential to ensuring equitable representation and improving clinical applicability of RCT findings.

Для цитирования: Elmasry Sandra, Pasha Shabana, Kaur Manreet, Leighton Jonathan A, Gurudu Suryakanth R, Ha Christina. Most of moderate to severe ulcerative colitis patients in academic clinical practice still do not qualify for randomized controlled trials.. Crohn's & colitis 360. 2026. DOI: 10.1093/crocol/otag092.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.